Considering the possibility that GnRH agonist therapy might have influenced the onset or progression of Graves' disease, and after discussing the risks and benefits with her guardians, we discontinued GnRH agonist therapy, particularly since the patient was now managing menses adequately and there were no concerns regarding her predicted adult height. The gene discussed is GNRH1; the disease is Graves disease.